<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862043</url>
  </required_header>
  <id_info>
    <org_study_id>FIBHGM-SIOVAC</org_study_id>
    <secondary_id>2007-007033-40</secondary_id>
    <secondary_id>EC07-90772</secondary_id>
    <nct_id>NCT00862043</nct_id>
  </id_info>
  <brief_title>Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease</brief_title>
  <acronym>SIOVAC</acronym>
  <official_title>Sildenafil for Improving Outcomes After Valvular Correction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación de Investigación en Red en Enfermedades Cardiovasculares</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy of the mid-term treatment with&#xD;
      sildenafil in patients with persistent moderate or severe pulmonary hypertension (PH) after a&#xD;
      heart valve intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase IV, prospective, multicenter, randomized, double-blind, placebo-controlled,&#xD;
      academically funded clinical trial, with 6 months follow-up. A total of 354 patients will be&#xD;
      recruited. Inclusion criteria are: 1) successful surgical or percutaneous repair of a cardiac&#xD;
      valve at least one year before screening and 2) persistent moderate or severe PH, and 3)&#xD;
      absence of any residual significant valvular lesion. Patients will be randomized 1:1 to&#xD;
      received sildenafil 40 mg t.i.d. or placebo. The primary endpoint is a clinical composite&#xD;
      score combining: all-cause mortality, hospital admission for heart failure, World Health&#xD;
      Organization (WHO) functional class, and the patient global assessment score. Additional&#xD;
      clinical and mechanistic secondary end-points are defined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Outcome End-Point: all-cause mortality or hospital admission for heart failure, worsening of World Health Organization (WHO) functional class, or of the patient global assessment score</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to the sixth month in the in the six-minute walk test</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on WHO functional capacity</measure>
    <time_frame>3 &amp; 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admissions caused by or related to heart failure in each patient</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of progression/regression of tricuspid regurgitation by Doppler-echocardiography</measure>
    <time_frame>3 &amp; 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on right ventricular (RV) dimensions and function assessed by Doppler echocardiography</measure>
    <time_frame>3 &amp; 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on RV volumes and function assessed by cardiac magnetic resonance</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on the right catheterization hemodynamic parameters</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify patients who are more likely to respond to therapy by pharmacogenetics analysis</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Valvular Heart Disease</condition>
  <arm_group>
    <arm_group_label>Sildenafil Citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil Citrate 40 mg t.i.d. oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sildenafil-matched oral placebo 40 mg t.i.d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate</intervention_name>
    <description>40 mg t.i.d.</description>
    <arm_group_label>Sildenafil Citrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo t.i.d.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age at the date of selection ≥ 18 years&#xD;
&#xD;
          -  Mean pulmonary pressure ≥ 30 mmHg, measured by a Swan-Ganz catheter placed in the&#xD;
             pulmonary artery&#xD;
&#xD;
          -  Heart valve intervention: surgical or percutaneous replacement, repair or dilatation&#xD;
             performed at least one year before inclusion&#xD;
&#xD;
          -  Stable clinical condition for at least one month, without hospital admissions for&#xD;
             heart failure, and on appropriate and stable doses of conventional cardiovascular&#xD;
             medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requiring or likely to require the following medications: organic nitrates,&#xD;
             alpha-blocker therapy, potent cytochrome P450 3A4 inhibitors (erythromycin,&#xD;
             ketoconazole, cimetidine, HIV protease inhibitors such ritonavir and saquinavir)&#xD;
             Patients who have suffered a myocardial infarction, stroke, or life-threatening&#xD;
             arrhythmia within the last 6 months.&#xD;
&#xD;
          -  Patients with resting hypotension, with systolic blood pressure &lt; 90 mmHg&#xD;
&#xD;
          -  Patients with retinitis pigmentosa&#xD;
&#xD;
          -  Anatomical deformation of the penis (such as angulation, cavernosal fibrosis or&#xD;
             Peyronie's disease) or patients who have conditions which may predispose them to&#xD;
             priapism (such as sickle cell anemia, multiple myeloma, or leukemia)&#xD;
&#xD;
          -  Severe renal impairment with creatinine clearance &lt; 30 ml/min&#xD;
&#xD;
          -  Significant hepatic dysfunction&#xD;
&#xD;
          -  Prosthesis or valvular dysfunction with hemodynamic repercussion.&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Patients unlikely to cooperate in the study or with inability or unwillingness to give&#xD;
             informed consent&#xD;
&#xD;
          -  Life expectancy less than 2 years due to non-cardiac disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Bermejo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Maranon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Alava</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital German Trias y Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu y San Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelon</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación de Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao</name>
      <address>
        <city>Galdakao</city>
        <state>Vizcaya</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Canalejo</name>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Leon</name>
      <address>
        <city>Leon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.mineco.gob.es</url>
    <description>Funding Agent</description>
  </link>
  <link>
    <url>http://www.isciii.es/htdocs/index.jsp</url>
    <description>Funding Agent</description>
  </link>
  <link>
    <url>http://www.redcardiovascular.com</url>
    <description>Cardiovascular Research Spanish National Network</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>March 13, 2009</study_first_submitted>
  <study_first_submitted_qc>March 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2009</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary Pulmonary Hypertension</keyword>
  <keyword>Valvular Heart Disease</keyword>
  <keyword>Phosphodiesterase-Inhibitors</keyword>
  <keyword>Sildenafil</keyword>
  <keyword>Outcomes Research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

